Literature DB >> 20494320

Discrepant findings in immune responses to JC virus in patients receiving natalizumab.

Chen S Tan, Yiping Chen, Raphael P Viscidi, R Philip Kinkel, Marion C Stein, Igor J Koralnik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20494320      PMCID： PMC3817610          DOI： 10.1016/S1474-4422(10)70124-1

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  5 in total

1.  PML risk and natalizumab: more questions than answers.

Authors:  Richard M Ransohoff
Journal:  Lancet Neurol       Date:  2010-01-29       Impact factor: 44.182

2.  Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.

Authors:  Samantha Jilek; Emilie Jaquiéry; Hans H Hirsch; Andreas Lysandropoulos; Mathieu Canales; Laurence Guignard; Myriam Schluep; Giuseppe Pantaleo; Renaud A Du Pasquier
Journal:  Lancet Neurol       Date:  2010-01-29       Impact factor: 44.182

3.  Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals.

Authors:  R A Du Pasquier; J E Schmitz; J Jean-Jacques; Y Zheng; J Gordon; K Khalili; N L Letvin; I J Koralnik
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

4.  Asymptomatic reactivation of JC virus in patients treated with natalizumab.

Authors:  Yiping Chen; Evelyn Bord; Troy Tompkins; Janice Miller; Chen S Tan; R Philip Kinkel; Marion C Stein; Raphael P Viscidi; Long H Ngo; Igor J Koralnik
Journal:  N Engl J Med       Date:  2009-09-10       Impact factor: 91.245

5.  A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy.

Authors:  Renaud A Du Pasquier; Marcelo J Kuroda; Yue Zheng; Jims Jean-Jacques; Norman L Letvin; Igor J Koralnik
Journal:  Brain       Date:  2004-06-23       Impact factor: 13.501
  5 in total
  5 in total

Review 1.  Managing MS in a changing treatment landscape.

Authors:  Martin Duddy; Aiden Haghikia; Eleonora Cocco; Christian Eggers; Jelena Drulovic; Olga Carmona; Helene Zéphir; Ralf Gold
Journal:  J Neurol       Date:  2011-03-25       Impact factor: 4.849

2.  [Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].

Authors:  C Warnke; O Adams; R Gold; H-P Hartung; R Hohlfeld; H Wiendl; B C Kieseier
Journal:  Nervenarzt       Date:  2011-04       Impact factor: 1.214

3.  Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Clemens Warnke; Gloria von Geldern; Philipp Markwerth; Thomas Dehmel; Robert Hoepner; Ralf Gold; Michael Pawlita; Tania Kümpfel; Mathias Mäurer; Martin Stangel; Florian Wegner; Reinhard Hohlfeld; Vera Straeten; Volker Limmroth; Thomas Weber; Derik Hermsen; Christoph Kleinschnitz; Hans-Peter Hartung; Mike P Wattjes; Anders Svenningson; Eugene Major; Tomas Olsson; Bernd C Kieseier; Ortwin Adams
Journal:  Ann Neurol       Date:  2014-05-08       Impact factor: 10.422

4.  Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.

Authors:  A Laroni; C G Giacomazzi; L Grimaldi; P Gallo; M P Sormani; A Bertolotto; J L McDermott; I Gandoglia; I Martini; G Vitello; F Rinaldi; L Barzon; V Militello; M Pizzorno; F Bandini; E Capello; G Palù; A Uccelli; G L Mancardi; O E Varnier
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-16       Impact factor: 4.147

5.  Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Molly R Perkins; Caroline Ryschkewitsch; Julia C Liebner; Maria Chiara G Monaco; Danielle Himelfarb; Sara Ireland; Annelys Roque; Heather L Edward; Peter N Jensen; Gina Remington; Thomas Abraham; Jaspreet Abraham; Benjamin Greenberg; Charles Kaufman; Chris LaGanke; Nancy L Monson; Xiaoning Xu; Elliot Frohman; Eugene O Major; Daniel C Douek
Journal:  PLoS Pathog       Date:  2012-11-08       Impact factor: 6.823
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.